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Introduction
Soft tissue sarcomas (STS) are a relatively rare, het-
erogeneous group  of  tumors that  arise from  mes-
enchymal tissue. It is estimated 8300 new cases of
STS were diagnosed in the United States in 2002.1
The treatment of STS has been primarily surgical,
with adjuvant therapy based on the size of the tumor,
grade, and  margin  status. Using  a  multimodality
approach, local recurrence rates are less than 20% of
patients with STS of the extremity.2 Adequate control
of intra-abdominal and retroperitoneal tumors has
been more problematic. Despite signi￿ cant improve-
ments in the rates of local control and limb salvage,it
is the development of distant metastases that remains
the major determinant of mortality from STS.
Approximately 20–38% of patients with STS will
eventually develop metastatic  disease.3–6 The lungs
are the predominant sites of distant disease.Although
less common, metastases to lymph nodes, the liver,
the  peritoneum, soft  tissue, bone, and  the  central
nervous  system  also  occur. The  development  of
regional and/or distant metastases is associated with
extremely poor survival.
Several  factors  have  been  associated  with  the
survival of sarcoma patients with metastatic disease.
These include age, surgical treatment of the metas-
tases, local  recurrence, and  tumor  size.4,7 A
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Abstract 
Introduction:There is a strong association between poor overall survival and a short disease-free interval for patients with
soft tissue sarcomas (STS) and metastatic disease.Patients with STS and synchronous metastases should have a very dismal
prognosis.The role of surgery in this subgroup of patients with STS has not been de￿ ned.
Patients and Methods: A single-institution retrospective review was performed of 48 patients with STS and synchronous
metastases in regard to patient demographics, presentation,tumor characteristics, metastatic sites, treatment, follow-up, and
survival over a 27-year period.
Results: Most primary tumors were ‡10 cm (58%), high-grade histology (77%), and located on the extremity (60%).The
most frequent site of metastatic disease was the lung (63%); 27% of patients had metastases to ‡ 2 organ sites. Surgery to
the primary tumor was performed in 94% of patients (n = 45) and 68% had additional radiation therapy (n = 32).Thirty-
￿ ve percent of patients underwent at least one metastastectomy (n = 17).Chemotherapy was administered to 90% of patients
(n = 43); 31% received ‡3 different regimens (n = 15) and 25% were given intra-arterial or intracavitary therapy (n = 12).
Median overall survival was 15 months with a 21% 2-year survival.Local control of the primary tumor was achieved in 54%
(n = 26), and metastastectomy was performed in 35% (n = 17). No analyzed factors were associated with an improvement
in overall survival.
Conclusions: Despite multiple poor prognostic factors, the survival of patients with STS and metastases is comparable to
those who develop delayed metastatic disease. However, unlike patients who present with metachronous disease, there was
no improved survival observed for patients treated with metastastectomy. Consequently, treatment for patients with STS
and synchronous metastases should be approached with caution. Surgical management of STS with synchronous metas-
tases must be considered palliative and should be reserved for patients requiring palliation of symptoms. Patients must also
be well informed of the noncurative nature of the procedure.
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DOI: 10.1080/1357714021000022168prolonged disease-free interval from the time of diag-
nosis until the development of distant metastases has
also been linked to an improved survival.4,8,9 Based
on this observation, patients with STS and synchro-
nous metastases should have a dismal prognosis.
A dif￿ cult dilemma surrounds the management of
this group of patients with STS who present with
synchronous  metastases. Although  an  improved
survival  has  been  demonstrated  in  patients  with
surgically  resected  metachronous  metastases  with
STS,10,11 similar  information  is  not  available  for
patients with STS and synchronous metastases.The
purpose of this study was to describe the experience
at a tertiary care cancer center, identify prognostic
factors  associated  with  improved  survival, and  to
assess the  impact of surgical intervention on their
outcome.
Patients and methods
A retrospective review of the Roswell Park Cancer
Institute (RPCI) Tumor Registry from 1971 to 1998
was performed to identify patients with the diagnosis
of a soft tissue sarcoma and synchronous metastases.
Sarcomas felt to  be  of bone origin were excluded
from the review. Histological diagnosis of soft tissue
sarcoma  was  performed  or  con￿ rmed  by  RPCI
pathologists. Fifty-three  patients  were identi￿ ed as
having a soft tissue sarcoma with synchronous metas-
tases. Review of  the  medical  records revealed  ￿ ve
patients who did not meet the de￿ nition of synchro-
nous metastases. Four patients had delayed develop-
ment of  metastatic  disease and  one  patient  had  a
synchronous  second  non-sarcomatous  primary
tumor. Consequently, the study group for this study
consisted of 48 patients.The diagnosis of metastatic
disease  was  established  by  biopsy  of  suspicious
lesions or strongly suspected based on radiological
studies and con￿ rmed by subsequent progression of
disease. For the purpose of this study, synchronous
was de￿ ned as either: (1) metastatic disease present
at the time of pathological diagnosis of the primary
tumor, or (2) metastatic disease present at the time
of  the  ￿ rst  surgical  intervention  for  the  primary
tumor.
A complete review of the RPCI medical record and
available outside information was performed for all
patients  identi￿ ed  from  the  Tumor  Registry.
Information  obtained  included: patient  demo-
graphics  (age, gender, race), presentation  (symp-
toms, diagnosis, work-up), tumor  characteristics
(histology, size, location, metastatic sites), treatment
(surgery, chemotherapy, radiation), follow-up, and
survival.The study was approved by the Roswell Park
Cancer Institute Institutional Review Board. Patient
con￿ dentiality was maintained.
Estimated overall survival  was  calculated by  the
method of Kaplan and Meier. Tests of signi￿ cance
with respect to survival distributions were based on
the  log-rank  test. Statistical  signi￿ cance  for  all
analyses was de￿ ned as p < 0.05. All statistical cal-
culations were performed using SPSS for Windows
(ver. 6.1).
Results
Demographic information and tumor characteristics
for the 48 patients are summarized in Table 1. This
study population includes a wide variety of histolog-
ical subtypes.
The diagnosis of metastases was made pre-opera-
tively in 40 patients (83%) and at the time of the ￿ rst
surgery  in  eight  patients  (17%). Seventy-three
percent of patients (n = 35) had metastases limited
to one anatomic site at the time of diagnosis (Table
2). Synchronous pulmonary metastases  were most
commonly encountered (n = 30). Nodal disease was
found in 11 patients. Hepatic involvement was a rare
event (n = 4).
Surgery played an integral role at our institution in
the  treatment  of  both  the  primary tumor and the
metastatic disease. Forty-￿ ve patients underwent at
least one attempt at surgical resection of the primary
tumor and two or more operations were performed
on 13 patients. Seven patients had an unresectable
primary tumor at the time of surgical intervention,
three  of  which  had  concomitant  sarcomatosis.
Seventeen patients underwent at least one attempt at
metastasectomy. Resection of pulmonary metastases
was the most common procedure (n = 13) with four
patients undergoing two or more operations (Table
3). The median survival of patients who underwent
at  least  one  metastasectomy  procedure  was  16.0
versus 14 months for those with no attempt at resec-
tion of metastatic disease (Fig. 1, p = 0.3).
Chemotherapy  was  given  to  43  of  48  patients
(90%), with  15  patients  (31%)  receiving  three  or
more  different  chemotherapeutic  regimens. The
majority also received at least one regimen of doxoru-
bicin based therapy (n = 40, 93%). Seven patients
were treated with chemotherapy prior to any attempt
at surgical resection of the primary tumor. Twenty-
eight percent of patients receiving chemotherapy (n
= 12) were given at least one regimen through a non-
intravenous  route. Intra-arterial  doxorubicin  was
administered into the extremity in seven patients, via
the  hepatic  artery  in  three  patients, and  via  the
pulmonary artery in two patients.Cisplatin was given
intraperitoneally to two patients and intrathoracically
to  one  patient. Sixteen  patients  received radiation
therapy to the primary tumor site.
The overall median survival was 15.0 months. At
the time of last follow-up, 88% of the patients had
died (n = 42).Three patients are alive with disease at
15, 9, and 6 months.An additional three patients are
alive  with  no  evidence of  disease  at  19, 8, and  8
months. Overall survival is presented in Fig. 2. The
effect of various factors on overall survival is shown
in Table 4. None of the examined variables had a
statistically signi￿ cant impact on overall survival.
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The development of metastases from STS carries a
poor prognosis.With metastatic disease, 62–80% of
patients will have pulmonary metastases and 50–70%
will  have  isolated  pulmonary  metastases.4,8,10,12,13
Lymph  node  metastases  from  STS  are  generally
considered a rare event, present in only 2.6–16% of
all patients with STS.14,15 Approximately 1.2–6.6%
of all patients with STS develop soft tissue metas-
tases, usually as a late event associated with widely
disseminated  disease.16 Median  survival  following
the  diagnosis  of  metastatic  disease  ranges  from  8 
to  14.5  months.3,4,7,12 Two-year  overall  survival  is
20–28%, decreasing  to  10%  for  patients  with
multiple sites of metastatic disease.3,4,12 Several prog-
nostic  factors  for  overall  survival  of  patients  with
metastatic STS have been identi￿ ed.Tumor size >10
cm, local  recurrence, unresectable metastases, age
>50 years,and a disease-free interval <1 year have all
been associated with a decreased survival after the
development of metastases.4,7,8
The proportion of patients with STS who present
with synchronous metastatic disease ranges from 12
to 23% in uncontrolled series and represents a sub-
group of patients with no disease-free interval.5,6 Suit
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Table  1. Characteristics  of  48  patients  with  a  soft  tissue
sarcoma and synchronous metastases
Age (years)
Mean 44.8
Range 13–83
< 50  52% (25)
> 50 48% (23)
Sex
Male 60% (29)
Female 40% (19)
Race
Caucasian 88% (42)
African-American 8% (4)
Hispanic 4% (2)
Interval form symptoms to 
diagnosis (months)
Mean 6.7
Median 3.1
Range 0–36
Symptoms
Mass 67% (32)
Pain 60% (29)
Weight loss 8% (4)
Fevers 4% (2)
Size (cm) n=45
Mean 11
Range 2.5–40
< 10 42% (19)
> 10 58% (26)
Grade
High 77% (37)
Intermediate 8% (4)
Unspeci￿ ed 15% (7)
Site
Extremity 60% (29)
Intra-abdominal 27% (13)
Trunk 13% (6)
Histology
Leiomyosarcoma 21% (10)
Gastrointestinal stromal 
tumor (GIST) 15% (7)
Malignant ￿ brous 
histiocytoma 10% (5)
Synovial cell 10% (5)
Liposarcoma 6% (3)
Undifferentiated 6% (3)
Other 31% (15)
Table 2. Characteristics of the metastatic tumor in 48 patients
with a soft tissue sarcoma and synchronous metastases
Site
Lung 63% (30)
Lymph nodes 23% (11)
Peritoneal 19% (9)
Soft tissue/bone 17% (8)
Liver 8% (4)
Bone marrow 2% (1)
Number of sites
One 73% (35)
Two 23% (11)
Three 4% (2)
Table 3. Surgical treatment  of metastatic tumor  sites in 48 
patients with soft tissue sarcomas and synchronous metastases
Any metastasectomy
No 65% (31)
Yes 35% (17)
Number of pulmonary 
metastasectomies
None 73% (35)
One 19% (9)
‡Two 8% (4)
Range 0–4
Table 4. Effect of various factors on the overall survival in 48
patients with soft tissue sarcomas and synchronous metastases 
(statistically signi￿ cant at p < 0.05)
Variable p value
Sex 0.23
Age (< vs. ‡ 50 years) 0.53
Primary tumor histology 0.51
Grade 0.28
Size (< vs. ‡ 10 cm) 0.74
Primary tumor site 0.93
Number of surgeries at primary site 0.68
Residual tumor after primary surgery 0.93
Metastasectomy 0.30
Chemotherapy cycles (< vs. ‡ 3) 0.22
Pre-resection chemotherapy 0.81
Non-intravenous chemotherapy 0.58
Radiation to primary tumor site 0.69
Control of primary tumor site 0.60reported 1.6% of patients with tumors <5 cm had
synchronous  metastases  as  opposed  to  13%  for
tumors  >5cm.5 In  the  subgroup  of  patients  with
poorly  differentiated  tumors, >5cm, 20%  had
metastatic  disease  at  presentation. Those  patients
who present with synchronous metastases represent a
dif￿ cult subgroup to manage. Our approach to this
type  of  patient  has  been  traditionally  aggressive
surgery  for  the  primary  and  metastatic  sites. This
approach allows us to fully evaluate the role of surgery
in these patients.The median overall survival in this
series was 15.0 months with 21% of patients alive at
2 years.Ninety-four percent of patients had surgery at
the site of the primary tumor and local control was
eventually achieved in over one-half of all patients.
Thirty-￿ ve percent of patients underwent at least one
attempted metastastectomy; 76% of these were for
pulmonary metastases.Although the median survival
for patients undergoing metastastectomy was slightly
longer that of the patients deemed unresectable, the
difference was not statistically signi￿ cant.The bene￿ t
of pulmonary metastastectomy for STS in selected
patients with metachronous metastases has a 3-year
overall  survival  of  46–54%.10,11 Prognostic  factors
identi￿ ed for extended survival following pulmonary
metastastectomy  include  an  extended  disease-free
interval and complete metastasectomy.10,11,17
We did not observe an improved overall survival in
those  patients  who  underwent  metastastectomy
versus  those  deemed  unresectable. Several  factors
may present dif￿ culties in the interpretation of the
data. The patient population included in this series
was comprised of a small sample size identi￿ ed over
a 27-year period. During that period of time,medical
technology  has  evolved. For  example, computer
tomography most assuredly permitted earlier diag-
nosis  of  pulmonary  metastatic  disease  in  1998  as
compared  with  1971  when  only  chest  X-ray  was
available. Additionally, analysis  of  several  factors
failed  to  identify  any  variable  associated  with
improved overall survival. The uniform outcome of
the patients in our study is most likely due to the fact
that all patients had similar synchronous metastatic
tumor burdens that nulli￿ ed the predictive value of
standard prognostic factors.
Given the disseminated nature of their disease, the
majority of patients received systemic chemotherapy
(90%),usually consisting of at least one doxorubicin-
based regimen.The overall bene￿ t of chemotherapy
in  the  treatment  of  metastatic  STS  is  somewhat
controversial. Response rates have ranged from 15 
to  48%, but there has  been little  impact  on over-
all  survival.2,18,19 Approximately  one-third  of  the
patients  was  treated  with  three  or  more  different
chemotherapy regimens with no apparent impact on
survival. It  is  conceivable the various chemothera-
peutic regimens or radiation therapy had an impact
on survival.However,given the diversity of regimens,
the  heterogeneous  tumor  histology  present, varia-
tions in biological response to non-surgical therapy,
and the small sample size, it is impossible to deter-
mine the presence of any effect.
Despite  the  fact  that  there  is  no  disease-free
interval, the  survival  of  patients  with  STS  and
synchronous metastases is comparable to those who
develop delayed metastatic disease. However, there
does not appear to be any added survival bene￿ t of
metastastectomy for patients with STS and synchro-
nous metastases as has been observed in metastas-
tectomy for metachronous metastases. Although this
is a small retrospective series of patients over a large
period of time, the results appear to argue against the
72 Kane et al.
Fig. 1. Survival  by  surgery  for  metastatic  disease.
Kaplan–Meier survival curves are presented with reference to
surgical  intervention  for  STS  with  synchonous  metastases.
Survival for patients who underwent metastastectomy is repre-
sented by the solid line (n = 31; 26 failures; median survival 1
4 months). Survival for patients who did not undergo metas-
tastectomy is represented by the dashed line (n = 17;16 failures;
median survival 16 months).There was no difference in survival
(p = 0.3).
Fig. 2. Overall survival. A Kaplan–Meier curve is presented
for overall survival in for patients presenting with STS and
synchronous metastases (n = 48; 42 failures; median survival
15 months). Overall 2-year survival was 21%.surgical management for the purpose of extending
survival  for  patients  with  STS  and  synchronous
metastases. Clearly, there remains a role for surgery
in this group of patients when there is palliative intent
for  the  surgery, i.e., maintenance and/or improve-
ment in the quality of life. Nevertheless, the surgical
management of the patient who presents with STS
and  synchronous  metastatic  disease, must  be
approached  with  caution, the  goals, and  risks  of
morbidity and mortality of surgery clearly delineated,
and  patient  expectations  thoroughly  discussed.
Further  study  is  warranted  regarding  the  role  of
multimodality therapy in this dif￿ cult dilemma.
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